Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-cash Items (2016 - 2024)

Historic Non-cash Items for Heron Therapeutics (HRTX) over the last 10 years, with Q4 2024 value amounting to $9.6 million.

  • Heron Therapeutics' Non-cash Items fell 1581.21% to $9.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $9.6 million, marking a year-over-year decrease of 1581.21%. This contributed to the annual value of $9.6 million for FY2024, which is 1581.21% down from last year.
  • Heron Therapeutics' Non-cash Items amounted to $9.6 million in Q4 2024, which was down 1581.21% from $11.4 million recorded in Q4 2023.
  • Over the past 5 years, Heron Therapeutics' Non-cash Items peaked at $69.1 million during Q4 2020, and registered a low of $1.7 million during Q4 2021.
  • For the 4-year period, Heron Therapeutics' Non-cash Items averaged around $22.9 million, with its median value being $10.5 million (2023).
  • Its Non-cash Items has fluctuated over the past 5 years, first skyrocketed by 82921.57% in 2020, then tumbled by 9753.98% in 2021.
  • Heron Therapeutics' Non-cash Items (Quarter) stood at $69.1 million in 2020, then plummeted by 97.54% to $1.7 million in 2021, then surged by 570.0% to $11.4 million in 2023, then dropped by 15.81% to $9.6 million in 2024.
  • Its Non-cash Items stands at $9.6 million for Q4 2024, versus $11.4 million for Q4 2023 and $1.7 million for Q4 2021.